205701-85-5
| 中文名称 | 205701-85-5 |
|---|---|
| 中文同义词 | 化合物 T16811;化合物RWJ-51204 |
| 英文名称 | RWJ-51204 |
| 英文同义词 | RWJ-51204;Pyrido[1,2-a]benzimidazole-4-carboxamide, 5-(ethoxymethyl)-7-fluoro-N-(2-fluorophenyl)-1,2,3,5-tetrahydro-3-oxo-;RWJ51204,RWJ 51204 |
| CAS号 | 205701-85-5 |
| 分子式 | C21H19F2N3O3 |
| 分子量 | 399.39 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 205701-85-5.mol |
| 结构式 |  |
205701-85-5 性质
| 沸点 | 533.0±50.0 °C(Predicted) |
|---|---|
| 密度 | 1.41±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 酸度系数(pKa) | 10.81±0.70(Predicted) |
RWJ-51204 是 GABA(A) receptor 的部分激动剂，Ki 值为 0.2-2 nM。
Ki: 0.2-2 nM (GABA(A))
RWJ-51204 binds to receptors in the cerebral cortex, cerebellum, or medulla-spinal cord with K i ranging from 0.2 to 0.6 nM.
RWJ-51204 is orally active in anxiolytic efficacy tests. WJ 51204 dose-relatedly antagonizes PTZ-induced clonic convulsions when administered orally (ED 50 = 0.04 mg/kg). RWJ-51204 is effective in the conflict test in monkeys (ED 50 of approximately 0.5 mg/kg p.o.). RWJ-51204 potently impairs rotarod performance in rats (ED 50 = 0.12 mg/kg), and all rats given RWJ-51204 orally at 30 mg/kg exhibit sedation, reduced skeletal muscle tone, and impairment of rotarod performance.